Author:
Ubillos Itziar,Ayestaran Aintzane,Nhabomba Augusto J,Dosoo David,Vidal Marta,Jiménez Alfons,Jairoce Chenjerai,Sanz Hèctor,Aguilar Ruth,Williams Nana Aba,Díez-Padrisa Núria,Mpina Maximilian,Sorgho Hermann,Agnandji Selidji Todagbe,Kariuki Simon,Mordmüller Benjamin,Daubenberger Claudia,Asante Kwaku Poku,Owusu-Agyei Seth,Sacarlal Jahit,Aide Pedro,Aponte John J,Dutta Sheetij,Gyan Ben,Campo Joseph J,Valim Clarissa,Moncunill Gemma,Dobaño Carlota
Funder
National Institutes of Health
PATH Malaria Vaccine Initiative
Ministerio de Economía, Industria y Competitividad, Gobierno de España
EviMalaR
AGAUR-Catalonia
CERCA Program-Generalitat de Catalunya
Publisher
Springer Science and Business Media LLC
Reference50 articles.
1. WHO. World Malaria Report 2017. 2017. Available from:
http://www.who.int/malaria/publications/world-malaria-report-2017/en/
.
2. WHO. A framework for malaria elimination. 2017. Available from:
http://www.who.int/malaria/publications/atoz/9789241511988/en/
.
3. Benelli G, Beier JC. Current vector control challenges in the fight against malaria. Acta Trop. 2017;174:91–6.
4. von Seidlein L, Dondorp A. Fighting fire with fire: mass antimalarial drug administrations in an era of antimalarial resistance. Expert Rev Anti-Infect Ther. 2015;13(6):715–30.
5. White NJ, Pongtavornpinyo W, Maude RJ, Saralamba S, Aguas R, Stepniewska K, Lee SJ, Dondorp AM, White LJ, Day NP. Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance. Malar J. 2009;8:253.